Pre-Exposure Prophylaxis (PrEP)
What is PrEP?
PrEP is short for PreExposure Prophylaxis and may be part of comprehensive HIV prevention services in which HIV negative people who are at high risk, take antiretroviral medication daily to try to lower their chances of becoming infected with HIV if they are exposed to it. To date, PrEP has only been shown to be effective in men who have men who have sex with men (MSM) and transgendered women who have sex with men. Studies are underway to evaluate whether it is safe and effective in reducing HIV infection among heterosexual men and women as well as injection drug users, but those results are not yet available.
* Updated Fact Sheet: PRE-EXPOSURE PROPHYLAXIS (PrEP) FOR HIV PREVENTION: Promoting Safe and Effective Use in the United States Adobe PDF file Added on February 25, 2011
* Updated Fact Sheet: TRIALS: Pre-Exposure Prophylaxis for HIV Prevention: PrEP: A New Approach to HIV Prevention Adobe PDF file Added on February 25, 2011
* Media Statement: CDC issues interim guidance to health care providers on the use of pre-exposure prophylaxis (PrEP) as an HIV prevention strategy among men who have sex with menAdded on January 27, 2011
* Related Materials: CDC Interim PrEP Guidance GraphicAdded on January 27, 2011
* MMWR: Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men Added on January 27, 2011
In November 2010, the National Institutes of Health (NIH) announced the results of the iPrEx clinical trial, a large, multi-country research study examining whether a pill used to treat HIV can also help prevent HIV infection. The study found that daily oral use of tenofovir plus emtricitabine (brand name Truvada) provided an average of 44% additional protection to men who have sex with men (MSM) who also received a comprehensive package of prevention services that included monthly HIV testing, condom provision, and management of other sexually transmitted infections.
Full text available at link below –